A phase III trial to validate HP 129XE MRI as a functional pulmonary biomarker in pediatric lung disease
Ended Project Grant Awarded Last action
- Award ID
- R44HL123299
- Recipient
-
Polarean Inc. UEI FSULLJ5XFVF1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,978,230
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | -$0 | |
| Amendment | -$0 | |
| Amendment | -$0 | |
| Amendment | $979,115 | |
| Amendment | $999,402 | |
| Original award | $999,713 |
Quick answers
Who received award R44HL123299?
R44HL123299 was awarded to Polarean Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on July 15, 2014.
How much is award R44HL123299 worth?
$2,978,230 has been obligated on R44HL123299.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award